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ABSTRACT
Objective non-randomised studies suggest that 
endoscopic mucosal resection (eMr) is equally effective 
in removing large rectal adenomas as transanal 
endoscopic microsurgery (teM), but eMr might be more 
cost-effective and safer. this trial compares the clinical 
outcome and cost-effectiveness of teM and eMr for 
large rectal adenomas.
Design Patients with rectal adenomas ≥3 cm, without 
malignant features, were randomised (1:1) to eMr or 
teM, allowing endoscopic removal of residual adenoma 
at 3 months. Unexpected malignancies were excluded 
postrandomisation. Primary outcomes were recurrence 
within 24 months (aiming to demonstrate non-inferiority 
of eMr, upper limit 10%) and the number of recurrence-
free days alive and out of hospital.
Results two hundred and four patients were treated 
in 18 university and community hospitals. twenty-seven 
(13%) had unexpected cancer and were excluded from 
further analysis. Overall recurrence rates were 15% 
after eMr and 11% after teM; statistical non-inferiority 
was not reached. the numbers of recurrence-free days 
alive and out of hospital were similar (eMr 609±209, 
teM 652±188, p=0.16). complications occurred in 
18% (eMr) versus 26% (teM) (p=0.23), with major 
complications occurring in 1% (eMr) versus 8% (teM) 
(p=0.064). Quality-adjusted life years were equal in both 
groups. eMr was approximately €3000 cheaper and 
therefore more cost-effective.
Conclusion Under the statistical assumptions of this 
study, non-inferiority of eMr could not be demonstrated. 
However, eMr may have potential as the primary method 
of choice due to a tendency of lower complication rates 
and a better cost-effectiveness ratio. the high rate of 
unexpected cancers should be dealt with in further 
studies.
InTRODuCTIOn
Rectal cancer is a common disease in the Netherlands 
with approximately 4350 new cases annually.1 The 
incidence of rectal cancer is increased with high age, 
male sex and obesity, without ethnic preference.2–4 
In the pathogenesis, premalignant intraepithelial 
neoplasia in a rectal adenoma precedes the occur-
rence of invasive rectal cancer.5 6 Early endoscopic 
detection and removal of rectal adenomas prevents 
the development of rectal cancer and decreases 
rectal cancer related mortality.7 8 It can be expected 
that due to the worldwide increasing implementa-
tion of colorectal cancer screening programmes, 
the detection of adenomas will increase. For 
small adenomas, standard endoscopic therapies 
like simple snare polypectomy or one-step endo-
scopic mucosal resection (EMR) will suffice. When 
Significance of this study
What is already known on this subject?
 ► After single intervention, endoscopic mucosal 
resection (EMR) for large rectal adenomas 
appears to be less effective but safer than 
transanal endoscopic microsurgery (TEM). The 
effectiveness becomes similar, when a second 
resection of adenoma remnants is allowed. 
However, the added morbidity of re-treatment 
is unknown.
 ► The current evidence lacks comparative 
studies and is insufficient to make firm 
recommendations.
What are the new findings?
 ► Recurrence occurred more often than expected 
after both EMR and TEM. Non-inferiority of 
EMR could not be demonstrated, partly due to 
a small absolute difference in recurrence rates.
 ► EMR appears to be the more cost-effective 
technique.
 ► Both interventions were associated with 
significant postprocedural morbidity. 
Complications of TEM tended to be major more 
often.
 ► Another important finding was a rather high 
rate of unexpected malignancies in rectal 
adenomas that were endoscopically diagnosed 
as benign.
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rectal adenomas are large, however, these techniques will be 
inadequate.
Surgical treatment of large rectal adenomas has advanced 
rapidly; local resection techniques and staging techniques 
(endorectal ultrasonography in particular) have been improved. 
In the past, rectal adenomas that were too large for endoscopic 
removal were referred for transanal resection or even total 
mesorectal excision (TME). The former technique was associ-
ated with a high incidence of recurrences, whereas the latter 
had a high operative morbidity and long-term functional conse-
quences.9 10 In 1984, transanal endoscopic microsurgery (TEM) 
was introduced by Buess et al.11 Since its introduction, many 
surgical practices have adopted this technique as the standard 
therapy for large rectal adenomas. With TEM, the adenoma can 
be removed en bloc, by submucosal dissection or full-thickness 
rectal wall excision. TEM has been shown to be an efficacious 
and safe treatment, and superior to traditional transanal resec-
tion.9 12
The endoscopic treatment of large rectal adenomas has also 
evolved. Improvements of imaging techniques and endoscopic 
instruments have led to advanced endoscopic resection methods 
like EMR. This technique allows piecemeal removal of large 
polyps through submucosal lifting and multiple snare resections.
Although selection bias inevitably exists in case series, published 
studies suggest that TEM and EMR have comparable recurrence 
rates.13 Most recurrences can be treated again without requiring 
radical surgery. The literature furthermore suggests that EMR 
is associated with fewer complications and reduced hospital 
admission, without requiring general anaesthesia. This may lead 
to differences in costs and quality of life. We designed a multi-
centre randomised non-inferiority trial to compare the cost-ef-
fectiveness and cost-utility of TEM and EMR for the resection 
of large rectal adenomas.
PATIEnTS AnD mEThODS
Study design
The TRansanal endoscopic microsurgery vs. ENDoscopic 
mucosal resection (TREND) Study was designed as a randomised, 
open-label, non-inferiority trial conducted at 17 Dutch centres 
and 1 Belgian centre. The non-inferiority design was chosen 
because the potential advantages of EMR from a patient and 
societal perspective like a lower complication rate, reduced 
hospital admission and absence of a need for general anaesthesia 
were considered irrelevant, unless EMR could be proven at least 
as effective as TEM in preventing recurrences. The study coordi-
nator collected coded data at each study site. The study protocol 
was described previously.14
Patients
We recruited patients above 17 years of age, who had a large 
(≥3 cm), non-pedunculated rectal adenoma; at least 50% of the 
adenoma needed to be situated within 15 cm from the dentate 
line. All patients underwent white light endoscopy; adenomas 
were endoscopically assessed for any malignant features. In 
case of any suspicious features, endorectal ultrasound (EUS) 
was allowed to evaluate for deep submucosal invasion. EUS 
was not mandatory in the diagnostic workup. Biopsies of the 
lesion, if taken, did not show submucosal invasion at histopatho-
logical evaluation. Synchronous colonic lesions were excluded 
by complete colonoscopy. The general condition of patients 
permitted general and/or spinal anaesthesia (American Society of 
Anesthesiologists (ASA) classification 1–3). Every eligible patient 
was evaluated by a surgeon and a gastroenterologist, and both 
EMR and TEM were judged feasible. Patients with a suspicion 
of malignancy based on endoscopic features, biopsies or EUS, as 
well as patients with a life-threatening systemic disease or mori-
bund clinical condition (ASA classification IV–V), a non-correct-
able coagulopathy or other contraindications for rectal surgery 
were excluded. All patients provided written informed consent.
Randomisation
Randomisation was done by the central study coordinator using 
a web-based randomisation module. Computer-generated block 
randomisation with a 1:1 allocation ratio and concealed random 
block sizes of two, four and six patients were used. Randomis-
ation was stratified according to primary or recurrent nature of 
adenoma. Due to the invasive nature of the interventions and the 
logistics involved, neither the trial participants nor the investiga-
tors could be masked to group allocation.
Intervention strategies
TEM was performed as described by Buess.11 14 The rectal defect 
was closed in the transverse direction. When TEM turned out 
to be technically impossible after randomisation, patients under-
went subsequent EMR. EMR was performed as described by 
Karita and Hurlstone and argon plasma coagulation (APC) of the 
edges of the mucosal defect was prescribed in the protocol.14–16 
When it turned out that EMR was technically not possible after 
randomisation  or  when  EMR  failed  to  remove >90%  of  the 
adenoma, the patient subsequently underwent TEM. Standard 
discharge criteria were applied and included normal intake and 
mobility, and absence of fever.
In case of an unexpected submucosally invasive cancer despite 
adherence to the inclusion criteria, the patient was excluded 
after the histopathological evaluation (late exclusion).
After 3 months, follow-up endoscopy was performed for 
assessment of potential adenoma remnants. This procedure was 
performed by the treating endoscopist or, in patients who had 
undergone TEM, by the local endoscopist primarily involved in 
the study. Presumed residual disease was resected endoscopically 
and assessed histologically to confirm the presence of neoplasia. 
Residual disease at 3 months was not considered as recurrence; 
endoscopic intervention at 3 months was considered part of the 
primary treatment strategy.
Follow-up
All patients underwent surveillance endoscopies at 6 months, 12 
months and 24 months after the primary treatment procedure by 
an independent endoscopist, who was blinded for the allocated 
study arm. Targeted biopsies of presumed recurrent adenoma 
were taken for histopathological confirmation. Random biopsies 
Significance of this study
how might it impact on clinical practice in the foreseeable 
future?
 ► Data of this trial reflect daily practice in the Netherlands and 
Belgium, where gastroenterologists and surgeons with a 
specific dedication perform EMR and TEM. They have much 
lower case-volumes compared with the few expert centres 
dominating the current literature.
 ► EMR should be considered as a potential treatment 
alternative. EMR deserves further attention and development 
in expert centres, in order to coexist besides TEM, or become 
the better alternative, in the treatment portfolio for large 
rectal adenomas.
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were taken from apparently normally healed scars to detect 
occult recurrence. Recurrence was defined as per Higaki criteria, 
as the presence of tumour at or nearby (within 5 mm) the resec-
tion scar, or evidence of tumour with associated fold conver-
gence.17 Follow-up via telephone was performed by research 
nurses after 1 day, 2 weeks, 3 months, 6 months, 12 months and 
24 months.
Outcomes
The primary outcome was recurrence of neoplasia (adenoma 
remnants at 3 months were not considered as recurrence), and 
the number of days a patient was alive, outside the hospital 
and free of recurrence during the 2-year follow-up period. 
Secondary outcomes were complication rates, health-related 
and disease-specific quality of life as assessed by the EQ-5D-3L, 
SF-36, Wexner Continence Grading Scale and Colorectal Func-
tional Outcome (COREFO) questionnaires, anorectal function 
and costs.18–21
A blinded expert panel of two gastroenterologists and two 
surgeons assessed the severity (according to Clavien-Dindo) of 
all adverse events that occurred during the study and their relat-
edness to the study procedure.22 Discrepancies were discussed 
until consensus was reached.
Statistical analysis
The principal analysis consisted of an intention-to-treat compar-
ison of recurrence rates in the two treatment groups. The goal 
was to test for non-inferiority of EMR with respect to the 
primary outcome, and superiority with respect to secondary 
outcomes. Our previously published meta-analysis was used 
for sample size calculation.13 The margin of non-inferiority 
applied  in  the  TREND  Study was  6.7%.  It  was  assumed  that 
the  recurrence  rate  in  the  TEM  group  would  be  3.3%  and 
that EMR would be considered non-inferior if the recurrence 
percentage would remain below 10% at maximum.14 Assuming 
a baseline recurrence rate of 3.3% for both TEM and EMR, we 
would consider EMR to be non-inferior if the associated recur-
rence rate was less than 6.7 percentage points above the TEM 
recurrence percentage. We used a one-sided significance level 
of  0.05.  To  attain  a  power  of  80%,  89  patients were  needed 
in each group. The χ2 test was applied to compare recurrence 
rates. The number of days not spent in hospital was compared 
by the Wilcoxon rank-sum test. Quality of life questionnaires 
were analysed using linear mixed models. IBM SPSS Statistics 
V.22 was used for statistical analyses. The trial is registered in the 
Dutch Trial Registry, trial number NTR1422.
Economic evaluation
Cost-effectiveness (costs per recurrence-free patient) and cost-
utility (costs per quality-adjusted life year (QALY)) were assessed 
from a societal perspective for a time-horizon of 24 months. 
The societal perspective included the costs of healthcare (index 
interventions, interventions after 3 months, hospital stay, major 
related diagnostic and therapeutic interventions, consultations 
with inhospital medical specialists, paramedics or alternative 
healers, formal home care), the costs of sick leave from work 
and non-reimbursable out-of-pocket expenses (over-the-counter 
medication, incontinence pads, additional private help).
Quality and safety monitoring and interim analysis
Dutch and Belgian gastroenterologists and surgeons were 
eligible for participation in the trial if they had performed at 
least 10 EMR or TEM procedures of (colo)rectal lesions larger 
than 3 cm, respectively. Surgeons were required to have followed 
a formal training programme for TEM. Participating endosco-
pists mutually aligned EMR techniques after discussion in inves-
tigator meetings before including their first patient in the study. 
An expert panel evaluated a video-recorded procedure of each 
participating physician prior to commencement of the trial at 
that particular centre. All study procedures were monitored and 
video-recorded by a research nurse from the coordinating trial 
centre.
Serious adverse events (SAEs), according to the WHO defi-
nition, were reported to the institutional review board every 
3 months. After 88 study patients had been treated, the suspicion 
of a potential uneven distribution of SAEs between both rando-
misation arms arose. At that time, safety and effectiveness were 
assessed in an interim analysis to reveal any potential imbalances 
between the two groups. An independent Data Safety Moni-
toring Board (consisting of a surgeon, a gastroenterologist and 
a clinical epidemiologist) was instituted, which recommended 
proceeding with the trial according to its original protocol.
RESulTS
From February 2009 until September 2013, 209 patients with 
large rectal adenomas were randomised (EMR 106; TEM 103). 
Two patients in both groups withdrew consent. One patient 
with prostate carcinoma instead of rectal adenoma in the EMR 
group was excluded. After the exclusion of these 5 patients, 103 
patients in the EMR group and 101 patients in the TEM group 
were included in the analysis. In the EMR group, five patients 
underwent TEM because of EMR failure. In the TEM group, 
three patients underwent EMR because of TEM failure. Twen-
ty-seven patients (13%; EMR 15; TEM 12) had an unexpected 
malignancy and were excluded. One additional patient withdrew 
consent. Eventually, 176 patients were included in the long-term 
analyses (figure 1). Baseline characteristics of these patients were 
comparable (table 1). Characteristics of the 27 patients with 
unexpected rectal cancer (16 men, 68±9 years old, 41% ASA 1, 
59% ASA 2) were also comparable. Their rectal lesions measured 
47±12 mm, and were situated 6.4±3.6 cm from the anal verge. 
Most (74%) malignant lesions were sessile. Preoperative biopsies 
were taken in 26/27 patients, showing low-grade dysplasia in 19 
and high-grade dysplasia in 7.
Most EMR procedures were performed under sedation (77% 





an extended procedure (median of 2 EMR attempts, IQR 2–3). 
TEM was mostly  performed  under  general  anaesthesia  (94%; 
6% spinal anaesthesia). A full thickness excision was done in 75 
cases (84%); 78 adenomas were excised as single piece (88%). 
The  peritoneal  cavity  was  breeched  in  seven  cases  (8%);  two 
required conversion to transabdominal approach to close the 
defect. Histopathological evaluation of TEM specimens revealed 
complete margins (R0) in 59 cases (66%); margins were incom-
plete  (R1)  in  14  (16%)  and  unsure  (Rx)  in  16  cases  (18%). 
Further procedure characteristics are summarised in table 2. 
Patients undergoing EMR were hospitalised significantly shorter 
than those undergoing TEM (0 days vs 1 day; p<0.001).
During repeat endoscopy at 3 months, there were three 
patients with adenoma remnants in the TEM group; they under-
went snare resection (n=2) or biopsy (n=1) of the remnant. After 
EMR, there were three patients in whom adenoma remnants 
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were discovered through random biopsies of a normally 
appearing scar. As such, they did not undergo any additional 
treatment. The 13 patients with visible remnants after EMR 
underwent snare resection (n=4), APC (n=1), a combination 
(n=3) or a combination of cold biopsy and APC (n=5). Endo-





to an adenoma recurrence proportion of 0.276. Hence, it cannot 
be ruled out that the absolute difference in adenoma recurrence 
proportions between EMR and TEM will exceed the non-infe-
riority margin of 0.067 (table 3), an inconclusive study result.23 
The median time to recurrence was 7 months (IQR 6–12) after 
EMR and 12 months (IQR 7–21) after TEM (p=0.10). In four 
patients who underwent EMR (5%), occult recurrence was diag-
nosed from random biopsies in a normally healed scar. Of 87 
patients who had undergone EMR, three developed adenocar-
cinoma in a recurrence. The mean number of days that patients 
spent out of the hospital while free of recurrence was comparable 
between groups (609 (95% CI 557 to 654) in EMR, 652 (95% 
CI 612 to 690) in TEM, difference −44 (95% CI −100 to –16), 
p=0.15). Subsequent sensitivity analyses, excluding any unre-
lated admissions, maintained comparable numbers.
Any postprocedural complication occurred in 16 patients after 
EMR  (18%)  and 23  after TEM  (26%)  (OR 0.65  (0.32–1.33), 
p=0.23). Complications are further specified in table 3. Haem-
orrhage was the most common complication in both groups and 
repeat endoscopy was often performed. The Clavien-Dindo 
classification of postprocedural haemorrhage is specified in 
online supplementary table S1 (supplementary appendix). Major 
complications (Clavien-Dindo grade III-b and up) occurred in 
1% (EMR) versus 8% (TEM) (OR 0.14 (95% CI 0.02 to 1.13), 
p=0.064).
Anorectal manometry was performed before and 6 months 
after treatment in a subset of 24 study patients. Results of this 
study have been published before, demonstrating that anal 
sphincter pressure, anorectal reflexes, rectal sensation and 
compliance were not affected by adenoma resection.24 SF-36, 
EQ-5D-3L, Wexner and COREFO Scores are summarised in 
online supplementary tables S2–S6. Health related quality of 
life was comparable between groups. Patients undergoing TEM 
scored significantly less favourable on the Wexner Continence 
Grading Scale (p=0.026), although continence improved after 
adenoma resection regardless of allocated treatment. COREFO 
Scores were significantly higher after TEM in comparison with 
EMR, indicating worse function. Differences were more notable 
at short term.
Online supplementary table S7 shows the costs of inpatient 
and outpatient hospital resources, out-of-hospital care, informal 
care and out-of-pocket expenses. The mean total costs of the 
index interventions after summing the costs of EMR and TEM 
are € 777 (€ 681 to € 900) in the EMR group and € 2177 (€ 
2114 to € 2243) in the TEM group (p<0.001). There was a 
non-significant  difference  in  costs  (−€  1471  (−€  3428  to  € 
52)) of inpatient hospital days (p=0.115). The costs of major 
related procedures were comparable between groups. No differ-
ences in medical consultations, use of formal and informal 
home care, or out-of-pocket expenses were observed. The costs 
of lost working hours due to absence from work were compa-
rable (p=0.61). Table 4 shows the total and subtotal costs. EMR 
was associated with lower costs compared with TEM (−€3003 
(−€6353 to −€84)). Based on the generic Dutch general popula-
tion preferences, generated QALYs were comparable (EMR 1.73 
(1.65–1.80), TEM 1.73 (1.64–1.81), p=0.96). Online supple-
mentary figure S1 shows the cost-effectiveness plane of differ-
ences in costs versus differences in QALYs. The probability of 
EMR being cost-effective when compared with TEM is reflected 
in the ‘cost-effectiveness acceptability curve’ in online supple-
mentary figure S2. 
Tumour staging and additional treatment of the unexpected malig-
nancies are shown in table 5. After a follow-up of more than 4 years, 
overall  survival  was  100%.  One  locally  recurrent  rectal  cancer 
was detected 22 months after TEM during a planned surveillance 
endoscopy. Distant metastases were found in three patients during 
Figure 1 Enrolment and outcomes 190 mm ×142mm (300 × 300 DPI). EMR, endoscopic mucosal resection; TEM, transanal endoscopic 
microsurgery. 
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surveillance after TEM of a low-risk T1 cancer (all R0 resections); 
these consisted of pulmonary metastases in two patients and a soli-
tary liver metastasis in one. Three out of four patients with recurrent 
malignant disease or distant metastases were treated with curative 
intent with either additional surgery or radiotherapy.
DISCuSSIOn
In this randomised trial, EMR was evaluated as a non-inferior 
alternative for TEM for resection of large rectal adenomas. Due 
to unexpected high recurrence rates of both TEM and EMR, 
partly due to a small absolute difference in recurrence rates (4%), 
non-inferiority of EMR could not be demonstrated. We found an 
early remnant rate of 19% after EMR and 5% after TEM, and a 
recurrence rate of 15% and 11%, respectively. The number of days 
that patients spent out of the hospital while free of recurrence was 
comparable between groups.
With the point estimate for the EMR recurrence rate already 
above the one for TEM, we reported the one-sided 95% upper 
Table 1 Clinical and pathological characteristics of included patients at baseline
Characteristic EmR (n=88) TEm (n=89)
Sex—no. (%)
  Male 48 (54) 47 (53)
  Female 40 (46) 42 (47)
Age—years ± SD 67.4±11.3 67.5±10.0
American Society of Anesthesiologists classification –no. (%)
  I: healthy 51 (58) 40 (45)
  II: mild systemic disease 32 (36) 44 (49)
  III: severe systemic disease 5 (6) 5 (6)
Body mass index 25.6±4.1 26.1±3.2
Anticoagulant use—no. (%)
  Antiplatelet agents 11 (13) 11 (12)
  Vitamin K antagonists 12 (14) 14 (16)
Type of adenoma—no. (%)
  Primary 85 (97) 85 (96)
  Recurrent 3 (3) 4 (5)
Type of prior excision in case of recurrent adenoma—no.
  Transanal excision (ie, Parks) 1 1
  EMR 1 3
  Unknown technique 1 0
Number of rectal lesions ≥3 cm
  1 87 89
  2 1 0
Adenoma size—mm ± SD 48±15 45±17
Adenoma distance from anal verge—cm ± SD 4.9±3.8 5.5±4.4
Paris classification—no. (%)
  Ip 0 (0) 1 (1)
  Is (Is or Is + IIa or Is + Ip) 44 (50) 52 (59)
  IIa 23 (26) 12 (14)
  IIb 0 (0) 1 (1)
  Missing data 22 (25) 23 (26)
Kudo classification—no. (%)
  III-S 4 (5) 1 (1)
  III-L 21 (24) 15 (17)
  IV 27 (30) 20 (23)
  III-L + IV 5 (6) 4 (5)
  Missing data 32 (36) 49 (55)
Preoperative biopsy—no. (%)
  Low-grade dysplasia 59 (66) 55 (62)
  High-grade dysplasia 13 (15) 14 (16)
  No biopsy 14 (16) 18 (20)
  Missing data 3 (3) 2 (2)
Preoperative endoscopic ultrasound—no. (%)
  T0 16 (18) 22 (25)
  T1 9 (10) 9 (10)
  T2 1 (1) 0 (0)
  T3 0 (0) 0 (0)
No EUS 62 (70) 58 (65)
EMR, endoscopic mucosal resection; EUS, endorectal ultrasound; TEM, transanal endoscopic microsurgery.
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confidence limit in this non-inferiority study rather than its 
equivalent 90% two-sided CI.
The trial was conducted in 18 largely non-academic hospitals 
and in the absence of tertiary referral centres. EMR and TEM 
were performed by selected gastroenterologists and surgeons 
with a specific dedication to these procedures. In this setting, 
recurrence rates have turned out higher than anticipated. In a 
previous meta-analysis, we have shown that the effectiveness of 
EMR and TEM are similar, when allowing a second resection of 
adenoma remnants.13 These remnants can often be easily treated 
by repeat EMR or by minor interventions using simple snare 
resection, biopsy forceps or APC. Hypothesising that such early 
resection of adenoma remnants might reduce recurrence rates, 
any intervention at 3 months was part of the initial treatment 
strategy in our study protocol. Although the 3-month endoscopy 
was not performed in 22/89 TEM patients, this was the case 
in only 2/10 patients with recurrence after TEM. In the EMR 
group, APC was omitted in 16% of patients (n=12). However, 
recurrence was only observed in 2/12. Considering the observed 
TEM  recurrence  rate  (11%),  adhering  to  the  proposed  addi-
tional 6.7% for EMR would require over 270 patients per group 
to preserve a statistical power of 80%. In contrast, proportional 
adjustment of allowed EMR recurrence rates would be clinically 
unacceptable.
A more recent EMR study and review (with different inclusion 
criteria) report late recurrence rates of 16% to 20%.25 26 A large 
prospective EMR series in an highly specialised setting reports 
a late recurrence rate of only 4%.27 However, this percentage is 
importantly flawed by excluding 16% of patients, with residual 
disease at their first follow-up endoscopy from further recur-
rence analyses. The available TEM series are mainly case mixes 
of benign and malignant rectal lesions. An Italian series of TEM 
for rectal adenomas reports a 5.6% recurrence rate.28
Economic evaluation showed that EMR is cheaper than 
TEM in 99% of cases, saving approximately €3000 per patient, 
whereas a difference in QALYs could not be demonstrated. 
Therefore, from a health economic perspective, EMR is the pref-
erable treatment.
Both EMR and TEM were associated with significant postpro-
cedural morbidity. Repeat endoscopy for haemorrhage was often 
performed, even though endoscopic intervention was not always 
necessary. Currently, many study groups employ more permis-
sive definitions of clinically significant haemorrhage. Therefore, 
our numbers may be an overestimation. Although the distinction 
between major and minor complications was not significantly 
different between groups, higher patient numbers might have 
shown significance.
Self-reported functional outcome improved after adenoma resec-
tion regardless of allocated treatment. The differences in Wexner 
and COREFO Scores in favour of EMR, which were more notable 
at short term, may indicate a potential disadvantageous effect of 
the 4-cm TEM proctoscope or loss of compliance due to trans-
mural resection, although this is not supported by the literature.
A generally acknowledged advantage of TEM over EMR is 
the possibility to perform a single-piece excision, enabling accu-
rate histopathological assessment of resection margins. Unfor-
tunately, the rates of Rx and R1 of TEM specimens were 18% 
and  16%,  respectively.  The  cases  of  Rx  may  reflect  unfamil-
iarity of local pathologists with TEM specimens; the absence 
of centralised histopathological evaluation is a limitation of our 
study. However, the 16% R1 ratio is considered substandard in 
comparison with the current literature.
Table 2 Intervention and hospitalisation characteristics
Characteristic EmR (n=88) TEm (89) p
Median procedure time—minutes (IQR) 53 (35–90) 60 (44–84) 0.61
Median hospital stay—days (IQR) (range) 0 (0–1) (0–8) 1 (1–2) (0–84) <0.001
Endoscopic completeness of resection—no. (%) 76 (87) 84 (94) 0.11
Extended procedure (multiple attempts required) 5 (6) N/A
Median no. of attempts (IQR) 2 (2–3)
Intraprocedural events—no. (%) 0.03
  Haemorrhage 2 (2) 2 (2)
  Peritoneal breech 0 (0) 7 (8)
   Defect closed via TEM N/A 5
   Defect closed via transabdominal approach N/A 2
  Mortality 0 (0) 0 (0) 
  Other 2 (2) 0 (0)
Procedure failure (%) 5 (6) 3 (3) 0.50
  Subsequent TEM 5 N/A
  Subsequent EMR N/A 2
  Subsequent TME 0 1
  Subsequent oncological workup (suspected malignancy) 0 0
Histopathological classification—no. (%) 0.52
  Dysplasia NOS 2 (2) 5 (6)
  Low-grade dysplasia 39 (44) 38 (43)
  High-grade dysplasia 47 (53) 46 (52)
Histopathological completeness of resection— no. (%)
  R0—radical N/A 59 (66)
  R1—irradical N/A 14 (16)
  Rx—unsure 88 (100) 16 (18)
EMR, endoscopic mucosal resection; TEM, transanal endoscopic microsurgery; TME, total mesorectal excision.
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Table 3 Major outcomes
Outcome EmR (n=87) TEm (n=89) p
Follow-up endoscopy within 3 months—no. (%) 85 (98) 67 (75) <0.001
Surveillance endoscopy—no (%)
  6 months 82 78 0.13
  12 months 81 81 0.61
  24 months 79 85 0.22
Adenoma remnants at 3 months—no. (%) 16 (19) 3 (5) 0.008
Adenoma recurrence at 6months, 12 months or 24 months—no. (%) 13 (15) 10 (11) 0.23*
Number of recurrences during study follow-up
  1 10 7
  2 2 2
  3 1 1
Any adenoma remnant or recurrence during follow-up – no. (%) 23 (26) 11 (12) N/A†
Carcinoma in recurrence—no. (%) 3 (3) 0 (0) 0.24
Median time to recurrence—months (IQR) 6.8 (6.1–12.2) 12.0 (6.8–20.7) 0.10
Time alive, recurrence-free and out of hospital—days ± SD 609±209 652±188 0.16
Patients with complication—no. (%) 16 (18) 23 (26) 0.23
Patients with major complication—no (%) 1 (1%) 7 (8%) 0.064
No. of complications per patient
  1 12 20
  2 3 1
  3 1 2
Complications –no.
  Any 21 28
  Hemorrhage 19 15
  Suture dehiscence 1
  Perforation 1
  Rectal stenosis 4
  Ileus / gastroparesis 1
  Myocardial infarction 1
  Respiratory failure 1
  Urinary tract infection 1 3
  Other 2
Clavien-Dindo classification—no.
  I 3 8
  II 3 6
  III-a 14 7
  III-b 1 3
  IV 0 3
  V 0 1
*The null hypothesis that EMR would lead to an increase of at least 6.7 percentage points above the recurrence rate in the TEM group, is not rejected (p=0.23, Farrington and 
Manning)
†Not assessed, because the actual hypothesis testing according to protocol included the superiority of TEM concerning residual disease (underpinning the need for a second EMR 
procedure at 3 months as part of the primary intervention) and the non-inferiority of EMR concerning recurrent disease.
‡Other complications: 1x thrombophlebitis, treated with oral antibiotics; 1x abdominal pain associated with free air in the retroperitoneum.
EMR, endoscopic mucosal resection; TEM, transanal endoscopic microsurgery.
Table 4 Subtotal and total costs
EmR (n=87)
mean costs in € (BCa 95% CI)*
TEm (n=89)
mean costs in € (BCa 95% CI)*
Resource
  Healthcare 3730 (2825 to4729) 6668 (5136 to8629)
  Informal care and out-of-pocket 420 (247 to631) 791 (392 to1287)
  Production loss 964 (276 to1838) 659 (97 to1406)
Total 5115 (3876 to6532) 8118 (6067 to10602)
*BCa 95% CI: bias corrected and accelerated 95% CI.
EMR, endoscopic mucosal resection; TEM,  transanal endoscopic microsurgery.
 on 28 M
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Endoscopic submucosal dissection (ESD) was developed 
in Japan to enable endoscopic en bloc resection even in large 
lesions. A meta-analysis comparing the results of ESD and EMR 
has shown promising rates of en bloc resection, radical resec-
tions and recurrence. These rates were achieved at the expense 
of longer procedure times and higher complication rates.29 The 
short-term and long-term cost-effectiveness of ESD and EMR in 
the distal colon are currently investigated in a randomised trial.30
An important finding was the high rate of unexpected malig-
nancies  in  13%  of  large  non-pedunculated  rectal  polyps  that 
endoscopically appeared benign. This seems to be comparable 
to the existing literature in which large non-pedunculated 
adenomas harbour invasive disease between 6.9% and 14%.31–34 
The protocol predicted a 1.6%–3% cancer rate by strict adher-




risk factors for malignancy in the diagnostic workup of large 
rectal lesions extends beyond the scope of this study. Although 
training of accurate optical diagnosis of large colorectal lesions 
among endoscopists is strongly recommended, our data reflect 
its difficulty and emphasise the issue of sampling error in these 
large lesions. By late exclusion of unexpected malignancies, 
the study protocol has turned out to be a limitation of sound 
intention-to-treat-analyses.
The majority of these unexpected cancers were low risk T1. 
The need for completion surgery was significantly higher after 
EMR, but the proportion of radical TME was comparable 
between EMR and TEM. There was a tendency towards a higher 
permanent stoma rate after initial TEM, but numbers are too 
small  to draw any conclusion. Overall  survival was 100% and 
three of four recurrences that were found during more than 
4 years of follow-up were treated with curative intent.
In the EMR group, three patients were diagnosed with carci-
noma in a recurrence. In the first two patients, the primary 
adenoma  involved  95%  of  the  rectal  circumference.  Histo-
pathology of the numerous EMR pieces revealed high-grade 
dysplasia but no submucosal invasion. After 6 months, a rectal 
stenosis was seen, and biopsies revealed submucosally invasive 
cancer. In those cases, a sampling error of the pathological exam-
ination of the primary treatment may be the reason for missing 
the diagnosis earlier, as extensive lesions like these often lead to 
jars with more than 20 small pieces being sent to the patholo-
gist. The third patient had a persisting, benign looking, fibrotic 
ulcer during surveillance endoscopies after EMR of an adenoma, 
demonstrating high-grade dysplasia. Repeated biopsies were 
benign. After 1 year, EUS showed local rectal wall thickening, 
Table 5 Staging and additional treatment of the unexpected rectal cancers
EmR (n=15) TEm (n=12) p
pT-stage—no. (%) 0.33
  T1 12 (80) 10 (83)
  T2 1 (8) 2 (17)
  T3 2 (13) -
Sm-stage—no. (%) 0.55
  Sm1 3 (27) 2 (22)
  Sm2 2 (18) 2 (22)
  Sm3 2 (18) 4 (44)
  Not assessable 4 (36) 1 (11)
pn-stage—no. (%) 0.66
  n0 5 (33) 5 (42)
  nx 10 (67) 7 (58)
Differentiation grade—no. (%)
  Good-moderate 10 (83) 8 (73) 0.55
  moderate 2 (17) 2 (18)
  mucinous 0 (0) 1 (9)
Angioinvasion—no. (%) 0 (0) 0 (0) N/A
lymph invasion—no. (%) 0 (0) 0 (0) N/A
histopathological completeness of 
resection—no. (%)
0.04
  R0 8 (53)* 11 (92)†
  Rx 7 (47) 1 (8)
Additional therapy—no. (%) 0.04
  Surveillance 3 (20) 7 (58)
  Completion surgery 12 (80) 5 (42)
Type of completion surgery—no. (%) 0.04*
  Abdominoperineal resection 2 (17) 4 (80)
  low anterior resection 4 (33) 1 (20)
  TEm 6 (50) -
*EMR: R0 when the basal margins were free of malignancy.
†TEM: R0 when the basal and lateral margins were free of malignancy.
‡Remained not significant after performing the Bonferroni correction.
EMR, endoscopic mucosal resection; TEM,  transanal endoscopic microsurgery.
 on 28 M
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and biopsies revealed adenocarcinoma. The latter patient may 
have been misdiagnosed prior to randomisation; however, the 
interval seems relatively long to support this theory.
Although the number of patients included per participating 
centre was low, this does not reflect the actual annual EMR 
volume of the centres. First, at least half of the patients that were 
invited to participate declined because of preference for one or 
the other procedure. Second, lesions below 3 cm or extending 
too high in the sigmoid or too close to the dentate line had to be 
excluded. Third, the volume of rectal EMRs is maximally 25% 
of the total colonic EMRs.
Our data reflect daily practice in the Netherlands and Belgium. 
Although the participating centres are gradually acquiring a 
tertiary referral setting, they have much lower case-volumes 
compared with the few expert centres dominating the current 
literature. The high rates of unexpected malignancies as well 
as the rather high recurrence and complication rates stress the 
importance of centralisation of these technically demanding 
techniques. As advanced endoscopic and transanal surgical skills 
are difficult to measure objectively, protocolled prospective 
registration should be employed. Training programmes focusing 
on optical diagnosis during endoscopy and advanced endoscopic 
and surgical techniques are highly recommended.
In summary, under the statistical assumptions of this study 
non-inferiority could not be demonstrated. However, EMR may 
have potential due to a tendency of lower complication rates 
and a better cost-effectiveness ratio. The high rate of unexpected 
cancers should be dealt with in further studies.
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